Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process

Seer, Inc. (SEER) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process REDWOOD CITY, Calif., October 29, 2026 – Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the S

Original reporting
Published Oct 29, 2026, 8:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$SEER
Neutral
medium confidence
Mentioned
$SEER
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SEERNeutralMed
01

Why it matters

The Special Committee’s conclusion and unanimous rejection directly changes the market’s probability-weighted M&A scenario for Seer and may shift focus back to product and commercial progress in proteomics.

02

Market read

Traders should reassess near-term takeover odds and the stock’s sensitivity to future strategic alternatives after the committee’s rejection of the two named bids.

03

What to watch

The release does not disclose whether management will actively solicit other bids or what specific strategic alternatives are next, leaving uncertainty around future M&A timing.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Oct 29, 2026

Background

Seer disclosed two unsolicited, non-binding proposals submitted in late July 2026 by the Radoff-JEC Group and by Seer’s CEO/Chair Omid Farokhzad, each including cash plus contingent value rights.

Company-level read

Ticker impact

$SEERNeutralMedium confidence
Context

Seer says its Special Committee concluded its review and unanimously rejected unsolicited acquisition proposals at $2.55 and $2.45 per share plus CVRs.

Expected impact

Likely modest downside or volatility as the market re-prices the probability of a near-term sale.

Evidence & confidence

The filing is a primary disclosure of the committee’s decision to reject specific bids, which directly affects takeover expectations but does not provide new financial guidance or a new bid.

Market effects

Signals that proteomics platform companies may face active M&A interest, but this specific target remains independent.

Limited, company-specific Nasdaq-listed event.

Low, no cross-border transaction or regulatory action described.

Counterpoint

Rejection may clear the path for Seer to pursue alternative strategic options or strengthen its standalone valuation narrative, potentially supporting the stock if execution improves.

Key entities

  • Seer, Inc.

    Nasdaq-listed proteomics company whose board special committee rejected unsolicited acquisition proposals.

  • Special Committee of Seer’s Board of Directors

    Independent directors that evaluated unsolicited proposals and rejected them.

  • Radoff-JEC Group

    Submitted an unsolicited, non-binding proposal to acquire Seer for $2.55 per share plus a contingent value right.

  • Omid Farokhzad

    Seer Chair and CEO who submitted an unsolicited, non-binding proposal to acquire Seer for $2.45 per share plus two contingent value rights.

Related articles

$SEERMed

Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance

Seer, Inc. (SEER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance REDWOOD CITY, Calif. – November 10, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced fin

$SEERMed

Seer wins ITC staff backing for import ban on Nanomics products

Seer, Inc. (SEER) announced that the U.S. International Trade Commission's staff recommended an import ban on Nanomics' products, alleging patent infringement. The ITC is expected to make a final decision by year-end. Seer also reported recent patent victories in the U.S. and Europe. The company develops proteomics technology and is involved in a related lawsuit against Nanomics.

$SEERMedAI 8/10

Seer Inc. Q2 2026 Earnings: Revenue Misses $3.1 Million

Seer Inc. (Nasdaq: SEER) reported Q2 2026 revenue of $3.1 million, below consensus of $4.0 million, and a net loss of $0.31 per share versus a $0.22 loss expected. The company reaffirmed full-year 2026 revenue guidance of $16 million to $18 million. Shares fell about 2.78% after hours to $2.10.